Laurent, Dirk
Menarini Group (Germany) · Berlin-Chemie AG (Germany)
3 papers on CoChat
Most cited papers
- Verified
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 2,895
- Verified
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Bidard, F.-C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., Mouret-Reynier, M.-A., Sohn, J. H., Taylor, D., Harnden, K. K., et al. (2022) · Journal of Clinical Oncology
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 777
- Verified
Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial
Teufel, M., Schwenke, S., Seidel, H., Beckmann, G., Reischl, J., Vonk, R., Lenz, H.-J., Tabernero, J., Siena, S., Grothey, A., et al. (2015) · Journal of Clinical Oncology
Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer
Cited by 26
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free